Eglucent Rapid 100 Iu/ml 3 ml Cartridge

• Type 1 and type 2 diabetes mellitus

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Eglucent Rapid 100 Iu/ml 3 ml also causes some adverse impact on the body, most of which resolve without any medical attention. Some common side effects include:

• Hypoglycemia (low blood glucose level)
• tiredness, fast heartbeat, nervousness, shakiness, nausea, headache, cold sweat
• local reaction like redness, swelling or itching around the area of the insulin injection

Uncommon  

• lipodystrophy (fatty tissue at injection site may either shrink or thicken)
• cutaneous amyloidosis (lumps under the skin)

Seek medical attention in case of any unusual or severe side effects immediately

• Dosage of this injection determined by the doctor as per the type of disease and overall health condition of the patient. Correct way of injecting Eglucent Rapid 100 Iu/ml 3 ml under the skin teach by your healthcare provider.
• It should be taken 15 minutes before a meal or within 20 minutes after starting a meal. Do not stop the medication without doctor's advice.​
  

• Eglucent Rapid 100 Iu/ml 3 ml Cartridge is a fast-acting insulin with Insulin Lispro (100IU/ml) as an active ingredient. It starts working within 10-20 minutes after injecting.
• This injection acts similarly as like the insulin produced by the body. Insulin facilitates reuptake of glucose in muscle and fat cells and also blocks the release of glucose from the liver.
  
  

• Summut, AL* & Wall, S. (2000). Breaking through dementia by working with carers: a guide for GPs. Modern Medicine, 25(3), 14-22.
• Slim, S., Griffiths, M. J., & Gama, R. (2007). Icodextrin-still a cause for concern with blood glucose monitoring in continuous ambulatory peritoneal dialysis patients with diabetes. Annals of clinical biochemistry, 44(2), 196-197. https://pubmed.ncbi.nlm.nih.gov/17362588/
• Chen, J. W., Christiansen, J. S., & Lauritzen, T. (2003). Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes, Obesity & Metabolism, 5(4). https://pubmed.ncbi.nlm.nih.gov/12795655/
• Mohan, V., Mukherjee, J. J., Das, A. K., Seshadri, K., & Dasgupta, A. (2021). Initiation and intensification of insulin therapy in type 2 diabetes mellitus: Physician barriers and solutions–An Indian perspective. Endocrine and Metabolic Science, 4, 100103. https://www.academia.edu/85457311/Initiation_and_intensification_of_insulin_therapy_in_type_2_diabetes_mellitus_Physician_barriers_and_solutions_An_Indian_perspective
• Danne, T., Bangstad, H. J., Deeb, L., Jarosz‐Chobot, P., Mungaie, L., Saboo, B., ... & Hanas, R. (2014). Insulin treatment in children and adolescents with diabetes. Pediatric diabetes, 15. https://pubmed.ncbi.nlm.nih.gov/19754621/